http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 27 May 2026 07:02:48 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/Atea+presents+drug+interaction+data+for+hepatitis+C+treatment/26553373.html <p>Atea Pharmaceuticals Inc. (NASDAQ: AVIR) presented Phase 1 results showing its hepatitis C virus treatment combination of bemnifosbuvir and ruzasvir has a low risk of drug-drug interactions. The data was presented at the European Association for the Study of the Liver Congress in Barcelona.</p><p>The Phase 1 study in 20 healthy adults showed the combination was safe and well-tolerated when administered with omeprazole, a proton pump inhibitor commonly used by hepatitis C patients. Omeprazole at 20 mg did not affect plasma exposure to the drug combination, while a 40 mg dose only slightly reduced exposure.</p><p>A separate study evaluated interactions with digoxin http://www.streetinsider.com/Corporate+News/Atea+presents+drug+interaction+data+for+hepatitis+C+treatment/26553373.html Wed, 27 May 2026 07:02:48 -0400 AVIR http://www.streetinsider.com/FDA/Atea+presents+drug+interaction+data+for+hepatitis+C+treatment/26553373.html <p>Atea Pharmaceuticals Inc. (NASDAQ: AVIR) presented Phase 1 results showing its hepatitis C virus treatment combination of bemnifosbuvir and ruzasvir has a low risk of drug-drug interactions. The data was presented at the European Association for the Study of the Liver Congress in Barcelona.</p><p>The Phase 1 study in 20 healthy adults showed the combination was safe and well-tolerated when administered with omeprazole, a proton pump inhibitor commonly used by hepatitis C patients. Omeprazole at 20 mg did not affect plasma exposure to the drug combination, while a 40 mg dose only slightly reduced exposure.</p><p>A separate study evaluated interactions with digoxin http://www.streetinsider.com/FDA/Atea+presents+drug+interaction+data+for+hepatitis+C+treatment/26553373.html Wed, 27 May 2026 07:02:48 -0400 AVIR http://www.streetinsider.com/Press+Releases/Atea+Pharmaceuticals+Presents+New+Drug-Drug+Interaction+Results+Supporting+Potential+Best-in-Class+Profile+of+the+Regimen+of+Bemnifosbuvir+and+Ruzasvir+for+the+Treatment+of+Hepatitis+C+Virus+at+EASL+C/26553296.html <p>BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced Phase 1 results which further demonstrate that the fixed-dose combination regimen of bemnifosbuvir and ruzasvir (BEM/RZR) for the treatment of hepatitis C virus (HCV) has a low risk of drug-drug interaction. These results support the use of BEM/RZR with commonly used medications, including the proton pump inhibitor (PPI) omeprazole and the cholesterol-lowering drug rosuvastatin. The Company is also presenting data demonstrating high <em>in vitro</em> antiviral potency and <em>in vivo</em> efficacy for AT-587, its potential first-in-class direct-acting http://www.streetinsider.com/Press+Releases/Atea+Pharmaceuticals+Presents+New+Drug-Drug+Interaction+Results+Supporting+Potential+Best-in-Class+Profile+of+the+Regimen+of+Bemnifosbuvir+and+Ruzasvir+for+the+Treatment+of+Hepatitis+C+Virus+at+EASL+C/26553296.html Wed, 27 May 2026 07:00:00 -0400 A.50203831 A.50216777 AVIR O.00010924 O.49059080 O.54516537 http://www.streetinsider.com/Press+Releases/Atea+Pharmaceuticals+Presents+New+Drug-Drug+Interaction+Results+Supporting+Potential+Best-in-Class+Profile+of+the+Regimen+of+Bemnifosbuvir+and+Ruzasvir+for+the+Treatment+of+Hepatitis+C+Virus+at+EASL+C/26553296.html <p>BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced Phase 1 results which further demonstrate that the fixed-dose combination regimen of bemnifosbuvir and ruzasvir (BEM/RZR) for the treatment of hepatitis C virus (HCV) has a low risk of drug-drug interaction. These results support the use of BEM/RZR with commonly used medications, including the proton pump inhibitor (PPI) omeprazole and the cholesterol-lowering drug rosuvastatin. The Company is also presenting data demonstrating high <em>in vitro</em> antiviral potency and <em>in vivo</em> efficacy for AT-587, its potential first-in-class direct-acting http://www.streetinsider.com/Press+Releases/Atea+Pharmaceuticals+Presents+New+Drug-Drug+Interaction+Results+Supporting+Potential+Best-in-Class+Profile+of+the+Regimen+of+Bemnifosbuvir+and+Ruzasvir+for+the+Treatment+of+Hepatitis+C+Virus+at+EASL+C/26553296.html Wed, 27 May 2026 07:00:00 -0400 A.50203831 A.50216777 AVIR O.00010924 O.49059080 O.54516537 http://www.streetinsider.com/Press+Releases/Atea+Pharmaceuticals+Presents+New+Drug-Drug+Interaction+Results+Supporting+Potential+Best-in-Class+Profile+of+the+Regimen+of+Bemnifosbuvir+and+Ruzasvir+for+the+Treatment+of+Hepatitis+C+Virus+at+EASL+C/26553296.html <p>BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced Phase 1 results which further demonstrate that the fixed-dose combination regimen of bemnifosbuvir and ruzasvir (BEM/RZR) for the treatment of hepatitis C virus (HCV) has a low risk of drug-drug interaction. These results support the use of BEM/RZR with commonly used medications, including the proton pump inhibitor (PPI) omeprazole and the cholesterol-lowering drug rosuvastatin. The Company is also presenting data demonstrating high <em>in vitro</em> antiviral potency and <em>in vivo</em> efficacy for AT-587, its potential first-in-class direct-acting http://www.streetinsider.com/Press+Releases/Atea+Pharmaceuticals+Presents+New+Drug-Drug+Interaction+Results+Supporting+Potential+Best-in-Class+Profile+of+the+Regimen+of+Bemnifosbuvir+and+Ruzasvir+for+the+Treatment+of+Hepatitis+C+Virus+at+EASL+C/26553296.html Wed, 27 May 2026 07:00:00 -0400 A.50203831 A.50216777 AVIR O.00010924 O.49059080 O.54516537 http://www.streetinsider.com/Press+Releases/Atea+Pharmaceuticals+Presents+New+Drug-Drug+Interaction+Results+Supporting+Potential+Best-in-Class+Profile+of+the+Regimen+of+Bemnifosbuvir+and+Ruzasvir+for+the+Treatment+of+Hepatitis+C+Virus+at+EASL+C/26553296.html <p>BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced Phase 1 results which further demonstrate that the fixed-dose combination regimen of bemnifosbuvir and ruzasvir (BEM/RZR) for the treatment of hepatitis C virus (HCV) has a low risk of drug-drug interaction. These results support the use of BEM/RZR with commonly used medications, including the proton pump inhibitor (PPI) omeprazole and the cholesterol-lowering drug rosuvastatin. The Company is also presenting data demonstrating high <em>in vitro</em> antiviral potency and <em>in vivo</em> efficacy for AT-587, its potential first-in-class direct-acting http://www.streetinsider.com/Press+Releases/Atea+Pharmaceuticals+Presents+New+Drug-Drug+Interaction+Results+Supporting+Potential+Best-in-Class+Profile+of+the+Regimen+of+Bemnifosbuvir+and+Ruzasvir+for+the+Treatment+of+Hepatitis+C+Virus+at+EASL+C/26553296.html Wed, 27 May 2026 07:00:00 -0400 A.50203831 A.50216777 AVIR O.00010924 O.49059080 O.54516537 http://www.streetinsider.com/Press+Releases/Atea+Pharmaceuticals+Presents+New+Drug-Drug+Interaction+Results+Supporting+Potential+Best-in-Class+Profile+of+the+Regimen+of+Bemnifosbuvir+and+Ruzasvir+for+the+Treatment+of+Hepatitis+C+Virus+at+EASL+C/26553296.html <p>BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced Phase 1 results which further demonstrate that the fixed-dose combination regimen of bemnifosbuvir and ruzasvir (BEM/RZR) for the treatment of hepatitis C virus (HCV) has a low risk of drug-drug interaction. These results support the use of BEM/RZR with commonly used medications, including the proton pump inhibitor (PPI) omeprazole and the cholesterol-lowering drug rosuvastatin. The Company is also presenting data demonstrating high <em>in vitro</em> antiviral potency and <em>in vivo</em> efficacy for AT-587, its potential first-in-class direct-acting http://www.streetinsider.com/Press+Releases/Atea+Pharmaceuticals+Presents+New+Drug-Drug+Interaction+Results+Supporting+Potential+Best-in-Class+Profile+of+the+Regimen+of+Bemnifosbuvir+and+Ruzasvir+for+the+Treatment+of+Hepatitis+C+Virus+at+EASL+C/26553296.html Wed, 27 May 2026 07:00:00 -0400 A.50203831 A.50216777 AVIR O.00010924 O.49059080 O.54516537 http://www.streetinsider.com/Press+Releases/Atea+Pharmaceuticals+Presents+New+Drug-Drug+Interaction+Results+Supporting+Potential+Best-in-Class+Profile+of+the+Regimen+of+Bemnifosbuvir+and+Ruzasvir+for+the+Treatment+of+Hepatitis+C+Virus+at+EASL+C/26553296.html <p>BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced Phase 1 results which further demonstrate that the fixed-dose combination regimen of bemnifosbuvir and ruzasvir (BEM/RZR) for the treatment of hepatitis C virus (HCV) has a low risk of drug-drug interaction. These results support the use of BEM/RZR with commonly used medications, including the proton pump inhibitor (PPI) omeprazole and the cholesterol-lowering drug rosuvastatin. The Company is also presenting data demonstrating high <em>in vitro</em> antiviral potency and <em>in vivo</em> efficacy for AT-587, its potential first-in-class direct-acting http://www.streetinsider.com/Press+Releases/Atea+Pharmaceuticals+Presents+New+Drug-Drug+Interaction+Results+Supporting+Potential+Best-in-Class+Profile+of+the+Regimen+of+Bemnifosbuvir+and+Ruzasvir+for+the+Treatment+of+Hepatitis+C+Virus+at+EASL+C/26553296.html Wed, 27 May 2026 07:00:00 -0400 A.50203831 A.50216777 AVIR O.00010924 O.49059080 O.54516537 http://www.streetinsider.com/Globe+Newswire/Atea+Pharmaceuticals+Presents+New+Drug-Drug+Interaction+Results+Supporting+Potential+Best-in-Class+Profile+of+the+Regimen+of+Bemnifosbuvir+and+Ruzasvir+for+the+Treatment+of+Hepatitis+C+Virus+at+EASL+C/26553296.html <p>BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced Phase 1 results which further demonstrate that the fixed-dose combination regimen of bemnifosbuvir and ruzasvir (BEM/RZR) for the treatment of hepatitis C virus (HCV) has a low risk of drug-drug interaction. These results support the use of BEM/RZR with commonly used medications, including the proton pump inhibitor (PPI) omeprazole and the cholesterol-lowering drug rosuvastatin. The Company is also presenting data demonstrating high <em>in vitro</em> antiviral potency and <em>in vivo</em> efficacy for AT-587, its potential first-in-class direct-acting http://www.streetinsider.com/Globe+Newswire/Atea+Pharmaceuticals+Presents+New+Drug-Drug+Interaction+Results+Supporting+Potential+Best-in-Class+Profile+of+the+Regimen+of+Bemnifosbuvir+and+Ruzasvir+for+the+Treatment+of+Hepatitis+C+Virus+at+EASL+C/26553296.html Wed, 27 May 2026 07:00:00 -0400 A.50203831 A.50216777 AVIR O.00010924 O.49059080 O.54516537 http://www.streetinsider.com/Globe+Newswire/Atea+Pharmaceuticals+Presents+New+Drug-Drug+Interaction+Results+Supporting+Potential+Best-in-Class+Profile+of+the+Regimen+of+Bemnifosbuvir+and+Ruzasvir+for+the+Treatment+of+Hepatitis+C+Virus+at+EASL+C/26553296.html <p>BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced Phase 1 results which further demonstrate that the fixed-dose combination regimen of bemnifosbuvir and ruzasvir (BEM/RZR) for the treatment of hepatitis C virus (HCV) has a low risk of drug-drug interaction. These results support the use of BEM/RZR with commonly used medications, including the proton pump inhibitor (PPI) omeprazole and the cholesterol-lowering drug rosuvastatin. The Company is also presenting data demonstrating high <em>in vitro</em> antiviral potency and <em>in vivo</em> efficacy for AT-587, its potential first-in-class direct-acting http://www.streetinsider.com/Globe+Newswire/Atea+Pharmaceuticals+Presents+New+Drug-Drug+Interaction+Results+Supporting+Potential+Best-in-Class+Profile+of+the+Regimen+of+Bemnifosbuvir+and+Ruzasvir+for+the+Treatment+of+Hepatitis+C+Virus+at+EASL+C/26553296.html Wed, 27 May 2026 07:00:00 -0400 A.50203831 A.50216777 AVIR O.00010924 O.49059080 O.54516537 http://www.streetinsider.com/Globe+Newswire/Atea+Pharmaceuticals+Presents+New+Drug-Drug+Interaction+Results+Supporting+Potential+Best-in-Class+Profile+of+the+Regimen+of+Bemnifosbuvir+and+Ruzasvir+for+the+Treatment+of+Hepatitis+C+Virus+at+EASL+C/26553296.html <p>BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced Phase 1 results which further demonstrate that the fixed-dose combination regimen of bemnifosbuvir and ruzasvir (BEM/RZR) for the treatment of hepatitis C virus (HCV) has a low risk of drug-drug interaction. These results support the use of BEM/RZR with commonly used medications, including the proton pump inhibitor (PPI) omeprazole and the cholesterol-lowering drug rosuvastatin. The Company is also presenting data demonstrating high <em>in vitro</em> antiviral potency and <em>in vivo</em> efficacy for AT-587, its potential first-in-class direct-acting http://www.streetinsider.com/Globe+Newswire/Atea+Pharmaceuticals+Presents+New+Drug-Drug+Interaction+Results+Supporting+Potential+Best-in-Class+Profile+of+the+Regimen+of+Bemnifosbuvir+and+Ruzasvir+for+the+Treatment+of+Hepatitis+C+Virus+at+EASL+C/26553296.html Wed, 27 May 2026 07:00:00 -0400 A.50203831 A.50216777 AVIR O.00010924 O.49059080 O.54516537 http://www.streetinsider.com/Globe+Newswire/Atea+Pharmaceuticals+Presents+New+Drug-Drug+Interaction+Results+Supporting+Potential+Best-in-Class+Profile+of+the+Regimen+of+Bemnifosbuvir+and+Ruzasvir+for+the+Treatment+of+Hepatitis+C+Virus+at+EASL+C/26553296.html <p>BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced Phase 1 results which further demonstrate that the fixed-dose combination regimen of bemnifosbuvir and ruzasvir (BEM/RZR) for the treatment of hepatitis C virus (HCV) has a low risk of drug-drug interaction. These results support the use of BEM/RZR with commonly used medications, including the proton pump inhibitor (PPI) omeprazole and the cholesterol-lowering drug rosuvastatin. The Company is also presenting data demonstrating high <em>in vitro</em> antiviral potency and <em>in vivo</em> efficacy for AT-587, its potential first-in-class direct-acting http://www.streetinsider.com/Globe+Newswire/Atea+Pharmaceuticals+Presents+New+Drug-Drug+Interaction+Results+Supporting+Potential+Best-in-Class+Profile+of+the+Regimen+of+Bemnifosbuvir+and+Ruzasvir+for+the+Treatment+of+Hepatitis+C+Virus+at+EASL+C/26553296.html Wed, 27 May 2026 07:00:00 -0400 A.50203831 A.50216777 AVIR O.00010924 O.49059080 O.54516537 http://www.streetinsider.com/Globe+Newswire/Atea+Pharmaceuticals+Presents+New+Drug-Drug+Interaction+Results+Supporting+Potential+Best-in-Class+Profile+of+the+Regimen+of+Bemnifosbuvir+and+Ruzasvir+for+the+Treatment+of+Hepatitis+C+Virus+at+EASL+C/26553296.html <p>BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced Phase 1 results which further demonstrate that the fixed-dose combination regimen of bemnifosbuvir and ruzasvir (BEM/RZR) for the treatment of hepatitis C virus (HCV) has a low risk of drug-drug interaction. These results support the use of BEM/RZR with commonly used medications, including the proton pump inhibitor (PPI) omeprazole and the cholesterol-lowering drug rosuvastatin. The Company is also presenting data demonstrating high <em>in vitro</em> antiviral potency and <em>in vivo</em> efficacy for AT-587, its potential first-in-class direct-acting http://www.streetinsider.com/Globe+Newswire/Atea+Pharmaceuticals+Presents+New+Drug-Drug+Interaction+Results+Supporting+Potential+Best-in-Class+Profile+of+the+Regimen+of+Bemnifosbuvir+and+Ruzasvir+for+the+Treatment+of+Hepatitis+C+Virus+at+EASL+C/26553296.html Wed, 27 May 2026 07:00:00 -0400 A.50203831 A.50216777 AVIR O.00010924 O.49059080 O.54516537 http://www.streetinsider.com/Globe+Newswire/Atea+Pharmaceuticals+Presents+New+Drug-Drug+Interaction+Results+Supporting+Potential+Best-in-Class+Profile+of+the+Regimen+of+Bemnifosbuvir+and+Ruzasvir+for+the+Treatment+of+Hepatitis+C+Virus+at+EASL+C/26553296.html <p>BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced Phase 1 results which further demonstrate that the fixed-dose combination regimen of bemnifosbuvir and ruzasvir (BEM/RZR) for the treatment of hepatitis C virus (HCV) has a low risk of drug-drug interaction. These results support the use of BEM/RZR with commonly used medications, including the proton pump inhibitor (PPI) omeprazole and the cholesterol-lowering drug rosuvastatin. The Company is also presenting data demonstrating high <em>in vitro</em> antiviral potency and <em>in vivo</em> efficacy for AT-587, its potential first-in-class direct-acting http://www.streetinsider.com/Globe+Newswire/Atea+Pharmaceuticals+Presents+New+Drug-Drug+Interaction+Results+Supporting+Potential+Best-in-Class+Profile+of+the+Regimen+of+Bemnifosbuvir+and+Ruzasvir+for+the+Treatment+of+Hepatitis+C+Virus+at+EASL+C/26553296.html Wed, 27 May 2026 07:00:00 -0400 A.50203831 A.50216777 AVIR O.00010924 O.49059080 O.54516537 http://www.streetinsider.com/SEC+Filings/Form++4A++++++++Atea+Pharmaceuticals%2C+++++For%3A+May+18++Filed+by%3A+Murphy+Polly+A./26537245.html si-local-file:///var/storage/secattach/20260521/26537245.html http://www.streetinsider.com/SEC+Filings/Form++4A++++++++Atea+Pharmaceuticals%2C+++++For%3A+May+18++Filed+by%3A+Murphy+Polly+A./26537245.html Thu, 21 May 2026 18:30:00 -0400 AVIR O.49059080 http://www.streetinsider.com/SEC+Filings/Form++4A++++++++Atea+Pharmaceuticals%2C+++++For%3A+May+18++Filed+by%3A+Murphy+Polly+A./26537245.html si-local-file:///var/storage/secattach/20260521/26537245.html http://www.streetinsider.com/SEC+Filings/Form++4A++++++++Atea+Pharmaceuticals%2C+++++For%3A+May+18++Filed+by%3A+Murphy+Polly+A./26537245.html Thu, 21 May 2026 18:30:00 -0400 AVIR O.49059080 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Atea+Pharmaceuticals%2C+++++For%3A+May+18++Filed+by%3A+Murphy+Polly+A./26528573.html si-local-file:///var/storage/secattach/20260520/26528573.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Atea+Pharmaceuticals%2C+++++For%3A+May+18++Filed+by%3A+Murphy+Polly+A./26528573.html Wed, 20 May 2026 16:16:00 -0400 AVIR O.49059080 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Atea+Pharmaceuticals%2C+++++For%3A+May+18++Filed+by%3A+Murphy+Polly+A./26528573.html si-local-file:///var/storage/secattach/20260520/26528573.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Atea+Pharmaceuticals%2C+++++For%3A+May+18++Filed+by%3A+Murphy+Polly+A./26528573.html Wed, 20 May 2026 16:16:00 -0400 AVIR O.49059080 http://www.streetinsider.com/Press+Releases/Atea+Pharmaceuticals+to+Present+Three+Abstracts+at+EASL+2026+Congress+Highlighting+Progress+Across+Viral+Hepatitis+Pipeline/26481419.html <p>BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that three abstracts have been accepted for presentation at the European Association for the Study of the Liver (EASL) Congress 2026, taking place May 27-30th in Barcelona, Spain.</p> <p>The presentations include two posters supporting Atea’s fixed-dose combination regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, for the treatment of hepatitis C virus (HCV). Also being presented http://www.streetinsider.com/Press+Releases/Atea+Pharmaceuticals+to+Present+Three+Abstracts+at+EASL+2026+Congress+Highlighting+Progress+Across+Viral+Hepatitis+Pipeline/26481419.html Wed, 13 May 2026 07:00:00 -0400 A.50216777 AVIR O.49059080 O.54516537 http://www.streetinsider.com/Press+Releases/Atea+Pharmaceuticals+to+Present+Three+Abstracts+at+EASL+2026+Congress+Highlighting+Progress+Across+Viral+Hepatitis+Pipeline/26481419.html <p>BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that three abstracts have been accepted for presentation at the European Association for the Study of the Liver (EASL) Congress 2026, taking place May 27-30th in Barcelona, Spain.</p> <p>The presentations include two posters supporting Atea’s fixed-dose combination regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, for the treatment of hepatitis C virus (HCV). Also being presented http://www.streetinsider.com/Press+Releases/Atea+Pharmaceuticals+to+Present+Three+Abstracts+at+EASL+2026+Congress+Highlighting+Progress+Across+Viral+Hepatitis+Pipeline/26481419.html Wed, 13 May 2026 07:00:00 -0400 A.50216777 AVIR O.49059080 O.54516537 http://www.streetinsider.com/Press+Releases/Atea+Pharmaceuticals+to+Present+Three+Abstracts+at+EASL+2026+Congress+Highlighting+Progress+Across+Viral+Hepatitis+Pipeline/26481419.html <p>BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that three abstracts have been accepted for presentation at the European Association for the Study of the Liver (EASL) Congress 2026, taking place May 27-30th in Barcelona, Spain.</p> <p>The presentations include two posters supporting Atea’s fixed-dose combination regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, for the treatment of hepatitis C virus (HCV). Also being presented http://www.streetinsider.com/Press+Releases/Atea+Pharmaceuticals+to+Present+Three+Abstracts+at+EASL+2026+Congress+Highlighting+Progress+Across+Viral+Hepatitis+Pipeline/26481419.html Wed, 13 May 2026 07:00:00 -0400 A.50216777 AVIR O.49059080 O.54516537 http://www.streetinsider.com/Press+Releases/Atea+Pharmaceuticals+to+Present+Three+Abstracts+at+EASL+2026+Congress+Highlighting+Progress+Across+Viral+Hepatitis+Pipeline/26481419.html <p>BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that three abstracts have been accepted for presentation at the European Association for the Study of the Liver (EASL) Congress 2026, taking place May 27-30th in Barcelona, Spain.</p> <p>The presentations include two posters supporting Atea’s fixed-dose combination regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, for the treatment of hepatitis C virus (HCV). Also being presented http://www.streetinsider.com/Press+Releases/Atea+Pharmaceuticals+to+Present+Three+Abstracts+at+EASL+2026+Congress+Highlighting+Progress+Across+Viral+Hepatitis+Pipeline/26481419.html Wed, 13 May 2026 07:00:00 -0400 A.50216777 AVIR O.49059080 O.54516537 http://www.streetinsider.com/Globe+Newswire/Atea+Pharmaceuticals+to+Present+Three+Abstracts+at+EASL+2026+Congress+Highlighting+Progress+Across+Viral+Hepatitis+Pipeline/26481419.html <p>BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that three abstracts have been accepted for presentation at the European Association for the Study of the Liver (EASL) Congress 2026, taking place May 27-30th in Barcelona, Spain.</p> <p>The presentations include two posters supporting Atea’s fixed-dose combination regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, for the treatment of hepatitis C virus (HCV). Also being presented http://www.streetinsider.com/Globe+Newswire/Atea+Pharmaceuticals+to+Present+Three+Abstracts+at+EASL+2026+Congress+Highlighting+Progress+Across+Viral+Hepatitis+Pipeline/26481419.html Wed, 13 May 2026 07:00:00 -0400 A.50216777 AVIR O.49059080 O.54516537 http://www.streetinsider.com/Globe+Newswire/Atea+Pharmaceuticals+to+Present+Three+Abstracts+at+EASL+2026+Congress+Highlighting+Progress+Across+Viral+Hepatitis+Pipeline/26481419.html <p>BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that three abstracts have been accepted for presentation at the European Association for the Study of the Liver (EASL) Congress 2026, taking place May 27-30th in Barcelona, Spain.</p> <p>The presentations include two posters supporting Atea’s fixed-dose combination regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, for the treatment of hepatitis C virus (HCV). Also being presented http://www.streetinsider.com/Globe+Newswire/Atea+Pharmaceuticals+to+Present+Three+Abstracts+at+EASL+2026+Congress+Highlighting+Progress+Across+Viral+Hepatitis+Pipeline/26481419.html Wed, 13 May 2026 07:00:00 -0400 A.50216777 AVIR O.49059080 O.54516537 http://www.streetinsider.com/Globe+Newswire/Atea+Pharmaceuticals+to+Present+Three+Abstracts+at+EASL+2026+Congress+Highlighting+Progress+Across+Viral+Hepatitis+Pipeline/26481419.html <p>BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that three abstracts have been accepted for presentation at the European Association for the Study of the Liver (EASL) Congress 2026, taking place May 27-30th in Barcelona, Spain.</p> <p>The presentations include two posters supporting Atea’s fixed-dose combination regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, for the treatment of hepatitis C virus (HCV). Also being presented http://www.streetinsider.com/Globe+Newswire/Atea+Pharmaceuticals+to+Present+Three+Abstracts+at+EASL+2026+Congress+Highlighting+Progress+Across+Viral+Hepatitis+Pipeline/26481419.html Wed, 13 May 2026 07:00:00 -0400 A.50216777 AVIR O.49059080 O.54516537